JP2008535798A5 - - Google Patents

Download PDF

Info

Publication number
JP2008535798A5
JP2008535798A5 JP2008500972A JP2008500972A JP2008535798A5 JP 2008535798 A5 JP2008535798 A5 JP 2008535798A5 JP 2008500972 A JP2008500972 A JP 2008500972A JP 2008500972 A JP2008500972 A JP 2008500972A JP 2008535798 A5 JP2008535798 A5 JP 2008535798A5
Authority
JP
Japan
Prior art keywords
hematocrit
dose
weekly
hemoglobin
visit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008500972A
Other languages
English (en)
Other versions
JP5737826B2 (ja
JP2008535798A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/008620 external-priority patent/WO2006099154A1/en
Publication of JP2008535798A publication Critical patent/JP2008535798A/ja
Publication of JP2008535798A5 publication Critical patent/JP2008535798A5/ja
Application granted granted Critical
Publication of JP5737826B2 publication Critical patent/JP5737826B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Description

用量に関連したヘマトクリット値の増加は、ベースラインと16回目の来院の間で観察された。ヘマトクリット値の変化はそれぞれ、800μg/kg週2回および毎週の群、ならびに400、200、100、50、および25μg/kg用量レベルのコホートにおいてそれぞれ、+3.8%、+2.7%、-0.2%、+1.6%、+0.6%、および+0.1%あった。同様の知見はヘモグロビンについても見られた。
JP2008500972A 2005-03-11 2006-03-10 Vegfの阻害による貧血の処置 Expired - Fee Related JP5737826B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66063805P 2005-03-11 2005-03-11
US60/660,638 2005-03-11
PCT/US2006/008620 WO2006099154A1 (en) 2005-03-11 2006-03-10 Treating anemia by inhibition of vegf

Publications (3)

Publication Number Publication Date
JP2008535798A JP2008535798A (ja) 2008-09-04
JP2008535798A5 true JP2008535798A5 (ja) 2012-11-01
JP5737826B2 JP5737826B2 (ja) 2015-06-17

Family

ID=36676448

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008500972A Expired - Fee Related JP5737826B2 (ja) 2005-03-11 2006-03-10 Vegfの阻害による貧血の処置

Country Status (6)

Country Link
US (1) US7351411B2 (ja)
EP (1) EP1855708A1 (ja)
JP (1) JP5737826B2 (ja)
AU (1) AU2006223314A1 (ja)
CA (1) CA2598452A1 (ja)
WO (1) WO2006099154A1 (ja)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7070959B1 (en) * 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US8986253B2 (en) 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
US8408421B2 (en) 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
EP2334234A4 (en) 2008-09-19 2013-03-20 Tandem Diabetes Care Inc DEVICE FOR MEASURING THE CONCENTRATION OF A SOLVED SUBSTANCE AND CORRESPONDING METHOD
EP2932994B1 (en) 2009-07-30 2017-11-08 Tandem Diabetes Care, Inc. New o-ring seal, and delivery mechanism and portable infusion pump system related thereto
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
US9555186B2 (en) 2012-06-05 2017-01-31 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
NZ710658A (en) 2013-02-18 2019-12-20 Vegenics Pty Ltd Ligand binding molecules and uses thereof
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
LT3170005T (lt) 2014-07-18 2019-07-10 Sanofi Paciento, įtariamo, kad serga vėžiu, gydymo afliberceptu rezultato prognozavimo būdas
EP3377101A4 (en) * 2015-11-19 2019-08-07 Zhuhai Tairuishang Biopharm Ltd. VEGF BINDING METHODS AND COMPOSITIONS
IL260323B1 (en) 2015-12-30 2024-09-01 Kodiak Sciences Inc Antibodies and their conjugates
KR101685532B1 (ko) * 2016-04-26 2016-12-13 한국프라임제약주식회사 혈관내피성장인자 수용체 융합단백질
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
US12071476B2 (en) 2018-03-02 2024-08-27 Kodiak Sciences Inc. IL-6 antibodies and fusion constructs and conjugates thereof
US11426446B2 (en) 2018-03-08 2022-08-30 Coherus Biosciences, Inc. Stable aqueous formulations of aflibercept
US11667702B2 (en) 2018-03-08 2023-06-06 Coherus Biosciences, Inc. Stable aqueous formulations of aflibercept
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder
KR102426802B1 (ko) * 2019-12-23 2022-07-28 한국프라임제약주식회사 혈관내피성장인자 수용체 융합단백질을 포함하는 신생혈관형성 관련 질환의 예방 및 치료를 위한 약학조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US6342221B1 (en) 1999-04-28 2002-01-29 Board Of Regents, The University Of Texas System Antibody conjugate compositions for selectively inhibiting VEGF
AUPQ592100A0 (en) 2000-02-29 2000-03-23 Council Of The Queensland Institute Of Medical Research, The A method of treatment and prophylaxis
CA2534197A1 (en) * 2003-08-06 2005-02-24 Thomas Jefferson University Use of a vegf antagonist in combination with radiation therapy

Similar Documents

Publication Publication Date Title
JP2008535798A5 (ja)
WO2007146965A3 (en) Compounds for the treatment of periodontal disease
JP2010285439A5 (ja)
JP2005518433A5 (ja)
IL183357A0 (en) Oral medicament for the modified release of at least one active principle, in multimicrocapsule form
IL190227A (en) Phenyl derivatives - [1,2,4] - oxadiazole - 5 - On with a phenyl group, their use in medicine, pharmaceuticals containing them, and a process for preparing the pharmaceutical preparations
IL228904A0 (en) Use of milankiperan, or a suitable pharmaceutical salt, in the preparation of a drug for the treatment of fibromyalgia
WO2006050250A3 (en) Dose forms comprising vx-950 and their dosage regimen
IL207038A (en) History of Diazaspiro [5.5] Undecan, Pharmaceuticals Containing them, and their use in the preparation of drugs for the treatment or reduction of the risk of disease or inflammatory condition
WO2008153610A3 (en) Use of il-23 antagonists for treatment of infection
IL186127A (en) Subcutaneous preparations for the treatment of depression and methods for their preparation
WO2008115281A3 (en) Compounds for treating viral infections
WO2008073448A3 (en) Pharmaceutical formulations and methods for making the same
CL2007003444A1 (es) Compuestos derivados de pirrolo[3,2-c]piridina; composicion farmaceutica; y uso en el tratamiento de un trastorno hiperproliferativo o una enfermedad inflamatoria.
TWI315305B (en) Piperidin-4-yl-amide derivatives,pharmaceutical compositions comprising the same,process for preparing the same and the use thereof
WO2008108830A3 (en) Immunogenic and therapeutic compositions for streptococcus pyogenes
WO2008073982A3 (en) 5,6-dihydro-1h-pyridin-2-one compounds
IL195935A0 (en) 18-methyl-19-nor-androst-4-en 17,17-spiroether (18-methyl-19-nor-20-spirox-4-en-3-one) and pharmaceutical preparations containing the same
EP1916251A4 (en) ERIANINE SALTS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
EP2167490A4 (en) TRIAZOLE DERIVATIVES WITH ANTIPILY EFFECT, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THEM
WO2010005565A3 (en) Method of treating glycogen storage disease
WO2005072704A3 (en) Method of treating acute rhinosinusitis
WO2006078713A3 (en) Methotrexate combinations for treating inflammatory diseases
WO2006015970A3 (en) Medicaments for the prevention or treatment of alveolar pneumonia comprising an anticholinergic
WO2006133194A3 (en) Methods for treating viral infection with oral or injectible drug solution